Thrombospondins, their polymorphisms, and cardiovascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 9, 2007, Pages 1886-1894

  Stenina, Olga I ^a   Topol, Eric J ^b   Plow, Edward F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Endothelial cells; Myocardial infarction; Single nucleotide polymorphisms; Thrombospondin

Indexed keywords

CALCIUM BINDING PROTEIN; GLYCOPROTEIN; THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THROMBOSPONDIN 3; THROMBOSPONDIN 4; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CELL INTERACTION; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENE REPLICATION; GENETIC DATABASE; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; NONHUMAN; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SHORT SURVEY;

ADULT; CORONARY ARTERIOSCLEROSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOSPONDINS;

EID: 34548158023     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.141713     Document Type: Short Survey

References (92)

1. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedman M, Metivier J, Cannata R, O'Donnell CJ, Kottke-Marchant K, Murugesan G, Plow EF, Stenina O, Daley GQ. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104:2641-2644.
2. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998;101:982-992.
3. Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, Danielson KG, Iozzo RV, LaMarca M, McKinney CE, Ginns EI, Bornstein P. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol. 1998;140:419-430.
4. Hankenson KD, Hormuzdi SG, Meganck JA, Bornstein P. Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head. Mol Cell Biol. 2005;25:5599-5606.
5. Svensson L, Aszodi A, Heinegard D, Hunziker EB, Reinholt FP, Fassler R, Oldberg A. Cartilage oligomeric matrix protein-deficient mice have normal skeletal development. Mol Cell Biol. 2002;22:4366-4371.
6. Kyriakides TR, Rojnuckarin P, Reidy MA, Hankenson KD, Papayannopoulou T, Kaushansky K, Bornstein P. Megakaryocytes require thrombospondin-2 for normal platelet formation and function. Blood. 2003;101:3915-3923.
7. Hecht JT, Deere M, Putnam E, Cole W, Vertel B, Chen H, Lawler J. Characterization of cartilage oligomeric matrix protein (COMP) in human normal and pseudoachondroplasia musculoskeletal tissues. Matrix Biol. 1998;17:269-278.
8. Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, Mortier GR, Rimoin DL, Lachman RS, Gaines ES, et al. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet. 1995;10:330-336.
9. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol. 2000;12:634-640.
10. Adams JC. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol. 2001;17:25-51.
11. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001;107:929-934.
12. Yang Z, Kyriakides TR, Bornstein P. Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell. 2000;11:3353-3364.
13. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A. 1999;96:14888-14893.
14. Kyriakides TR, Tam JW, Bornstein P. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol. 1999;113:782-787.
15. Kyriakides TR, Zhu YH, Yang Z, Huynh G, Bornstein P. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol. 2001;159:1255-1262.
16. Kyriakides TR, Bornstein P. Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost. 2003;90:986-992.
17. Vischer P, Buddecke E. Different action of heparin and fucoidan on arterial smooth muscle cell proliferation and thrombospondin and fibronectin metabolism. Eur J Cell Biol. 1991;56:407-414.
18. Gao AG, Frazier WA. Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins. J Biol Chem. 1994;269:29650-29657.
19. Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem. 1996;271:21-24.
20. Adams JC, Kureishy N, Taylor AL. A role for syndecan-1 in coupling fascin spike formation by thrombospondin-1. J Cell Biol. 2001;152:1169-1182.
21. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol. 1988;107:2351-2361.
22. Lawler J, Hynes RO. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood. 1989;74:2022-2027.
23. Vischer P. Modulation of extracellular matrix proteins and the influence of fucoidan on cell proliferation of smooth muscle cells. Biochem Soc Trans. 1990;18:962-963.
24. Yabkowitz R, Dixit VM, Guo N, Roberts DD, Shimizu Y. Activated T-cell adhesion to thrombospondin is mediated by the alpha 4 beta 1 (VLA-4) and alpha 5 beta 1 (VLA-5) integrins. J Immunol. 1993;151:149-158.
25. Krutzsch HC, Choe BJ, Sipes JM, Guo N, Roberts DD. Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem. 1999;274:24080-24086.
26. Calzada MJ, Sipes JM, Krutzsch HC, Yurchenco PD, Annis DS, Mosher DF, Roberts DD. Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin. J Biol Chem. 2003;278:40679-40687.
27. Wang XQ, Frazier WA. The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2 beta1 integrin in vascular smooth muscle cells. Mol Biol Cell. 1998;9:865-874.
28. Patel MK, Lymn JS, Clunn GF, Hughes AD. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2107-2114.
29. Stouffer GA, Hu Z, Sajid M, Li H, Jin G, Nakada MT, Hanson SR, Runge MS. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 1998;97:907-915.
30. Manna PP, Frazier WA. The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A. J Immunol. 2003;170:3544-3553.
31. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41-48.
32. Pluskota E, Stenina OI, Krukovets I, Szpak D, Topol EJ, Plow EF. Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. Blood. 2005;106:3970-3978.
33. Stenina OI, Desai SY, Krukovets I, Kight K, Janigro D, Topol EJ, Plow EF. Thrombospondin-4 and its variants: expression and differential effects on endothelial cells. Circulation. 2003;108:1514-1519.
34. Riessen R, Kearney M, Lawler J, Isner JM. Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J. 1998;135:357-364.
35. Roth JJ, Gahtan V, Brown JL, Gerhard C, Swami VK, Rothman VL, Tulenko TN, Tuszynski GP. Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J Surg Res. 1998;74:11-16.
36. Zhao XM, Hu Y, Miller GG, Mitchell RN, Libby P. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. Circulation. 2001;103:525-531.
37. Narizhneva NV, Byers-Ward VJ, Quinn MJ, Zidar FJ, Plow EF, Topol EJ, Byzova TV. Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. J Biol Chem. 2004;279:21651-21657.
38. Nesselroth SM, Willis AI, Fuse S, Olson ET, Lawler J, Sumpio BE, Gahtan V. The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis. J Vasc Surg. 2001;33:595-600.
39. Lee T, Nesselroth SM, Olson ET, Esemuede N, Lawler J, Sumpio BE, Gahtan V. Thrombospondin-1-induced vascular smooth muscle cell chemotaxis: the role of the type 3 repeat and carboxyl terminal domains. J Cell Biochem. 2003;89:500-506.
40. Hogg PJ, Hotchkiss KA, Jimenez BM, Stathakis P, Chesterman CN. Interaction of platelet-derived growth factor with thrombospondin 1. Biochem J. 1997;326(Pt 3):709-716.
41. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res. 2006;71:785-793.
42. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood. 2007;109:1945-1952.
43. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem. 2006;281:26069-26080.
44. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, Roberts DD. Increasing survival of ischemic tissue by targeting CD47. Circ Res. 2007;100:712-720.
45. Miano JM, Vlasic N, Tota RR, Stemerman MB. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. A putative in vivo mechanism for autocrine growth. Arterioscler Thromb. 1993;13:211-219.
46. Sajid M, Hu Z, Guo H, Li H, Stouffer GA. Vascular expression of integrin-associated protein and thrombospondin increase after mechanical injury. J Investig Med. 2001;49:398-406.
47. Raugi GJ, Mullen JS, Bark DH, Okada T, Mayberg MR. Thrombospondin deposition in rat carotid artery injury. Am J Pathol. 1990;137:179-185.
48. Chen D, Guo K, Yang J, Frazier WA, Isner JM, Andres V. Vascular smooth muscle cell growth arrest on blockade of thrombospondin-1 requires p21(Cip1/WAF1). Am J Physiol. 1999;277:H1100-H1106.
49. Stenina OI, Krukovets I, Wang K, Zhou Z, Forudi F, Penn MS, Topol EJ, Plow EF. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003;107:3209-3215.
50. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. Glycosylation mediates upregulation of a potent antiangiogenic and proatherogenic protein, Thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem. 2006.
51. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6:1-12.
52. Sargiannidou I, Zhou J, Tuszynski GP. The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood). 2001;226:726-733.
53. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J, Entman ML. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111:2935-2942.
54. Adolph KW. Relative abundance of thrombospondin 2 and thrombospondin 3 mRNAs in human tissues. Biochem Biophys Res Commun. 1999;258:792-796.
55. Lawler J, Duquette M, Whittaker CA, Adams JC, McHenry K, DeSimone DW. Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J Cell Biol. 1993;120:1059-1067.
56. Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JP, Porter JG, Evelo CT, Duisters R, van Leeuwen RE, Janssen BJ, Debets JJ, Smits JF, Daemen MJ, Crijns HJ, Bornstein P, Pinto YM. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res. 2004; 95:515-522.
57. Tan FL, Moravec CS, Li J, Apperson-Hansen C, McCarthy PM, Young JB, Bond M. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A. 2002;99:11387-11392.
58. Rysa J, Leskinen H, Ilves M, Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension. 2005;45:927-933.
59. Anilkumar N, Annis DS, Mosher DF, Adams JC. Trimeric assembly of the C-terminal region of thrombospondin-1 or thrombospondin-2 is necessary for cell spreading and fascin spike organisation. J Cell Sci. 2002;115:2357-2366.
60. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347:1916-1923.
61. Boekholdt SM, Trip MD, Peters RJ, Engelen M, Boer JM, Feskens EJ, Zwinderman AH, Kastelein JJ, Reitsma PH. Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2002;22:e24-e27.
62. Wessel J, Topol EJ, Ji M, Meyer J, McCarthy JJ. Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J. 2004;147:905-909.
63. Peyvandi FPR, Ardissino D, Foco L, Bernardinelli L, Bauer K, et al. Vagaries of genetic association studies in complex diseases: thrombospondins and acute myocardial infarction. Blood. 2003;102:314a.
64. Kato TYA, Murase Y, Hirashiki A, Noda A, Yamada Y. Specific gene polymorphisms could be risk factors for coronary artery disease in individuals with or without hypertention. Circulation. 2003;108(suppl):IV-712.
65. Walton BWJ, Coresh J, Boerwinkle E. Thrombospondin-2 and Lymphotoxin-a gene variations predict coronary heart disease in a large prospective study. Circulation. 2003;108(suppl):IV-771.
66. McCarthy JJ, Parker A, Salem R, Moliterno DJ, Wang Q, Plow EF, Rao S, Shen G, Rogers WJ, Newby LK, Cannata R, Glatt K, Topol EJ. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet. 2004;41:334-341.
67. Zhou X, Huang J, Chen J, Zhao J, Ge D, Yang W, Gu D. Genetic association analysis of myocardial infarction with thrombospondin-1 N700S variant in a Chinese population. Thromb Res. 2004;113:181-186.
68. Zhou X, Huang J, Chen J, Zhao J, Yang W, Wang X, Gu D. Thrombospondin-4 A387P polymorphism is not associated with coronary artery disease and myocardial infarction in the Chinese Han population. Clin Sci (Lond). 2004;106:495-500.
69. Cui J, Randell E, Renouf J, Sun G, Green R, Han FY, Xie YG. Thrombospondin-4 1186GC (A387P) is a sex-dependent risk factor for myocardial infarction: a large replication study with increased sample size from the same population. Am Heart J. 2006;152:543.e1-e5.
70. Cui J, Randell E, Renouf J, Sun G, Han FY, Younghusband B, Xie YG. Gender dependent association of thrombospondin-4 A387P polymorphism with myocardial infarction. Arterioscler Thromb Vasc Biol. 2004;24:e183-e184.
71. Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood. 2006;108:1280-1283.
72. Asselbergs FW, Pai JK, Pischon T, Manson JE, Rimm EB. Thrombospondin-4 Ala387Pro polymorphism is not associated with vascular function and risk of coronary heart disease in US men and women. Thromb Haemost. 2006;95:589-590.
73. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. Jama. 2007;297:1551-1561.
74. Detwiler TC, Turk JL, Browne PC. Thiol-disulfide exchange by thrombospondin. Semin Thromb Hemost. 1987;13:276-280.
75. Turk JL, Detwiler TC. Thiol-disulfide exchange by thrombospondin: evidence for a thiol and a disulfide bond protected by calcium. Arch Biochem Biophys. 1986;245:446-454.
76. Misenheimer TM, Mosher DF. Calcium ion binding to thrombospondin 1. J Biol Chem. 1995;270:1729-1733.
77. Chen H, Deere M, Hecht JT, Lawler J. Cartilage oligomeric matrix protein is a calcium-binding protein, and a mutation in its type 3 repeats causes conformational changes. J Biol Chem. 2000;275:26538-26544.
78. Hou J, Putkey JA, Hecht JT. Delta 469 mutation in the type 3 repeat calcium binding domain of cartilage oligomeric matrix protein (COMP) disrupts calcium binding. Cell Calcium. 2000;27:309-314.
79. Stenina OI, Ustinov V, Krukovets I, Marinic T, Topol EJ, Plow EF Polymorphisms. A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites. Faseb J. 2005;19:1893-1895.
80. 2+-binding repeats. J Biol Chem. 2003;278:8929-8934.
81. 2+ binding. J Biol Chem. 2004;279:51915-51922.
82. Gartner TK, Walz DA, Aiken M, Starr-Spires L, Ogilvie ML. Antibodies against a 23Kd heparin binding fragment of thrombospondin inhibit platelet aggregation. Biochem Biophys Res Commun. 1984;124:290-295.
83. Stenina OI, Byzova TV, Adams JC, McCarthy JJ, Topol EJ, Plow EF. Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol. 2004;36:1013-1030.
84. Inuzuka H, Nanbu-Wakao R, Masuho Y, Muramatsu M, Tojo H, Wakao H. Differential regulation of immediate early gene expression in preadipocyte cells through multiple signaling pathways. Biochem Biophys Res Commun. 1999;265:664-668.
85. Donohue PJ, Hsu DK, Guo Y, Burgess WH, Winkles JA. Fibroblast growth factor-1 induction of delayed-early mRNA expression in NIH 3T3 cells is prolonged by heparin addition. Exp Cell Res. 1997;234:139-146.
86. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31:3406-3415.
87. Lange-Asschenfeldt B, Weninger W, Velasco P, Kyriakides TR, von Andrian UH, Bornstein P, Detmar M. Increased and prolonged inflammation and angiogenesis in delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2- deficient mice. Blood. 2002;99:538-545.
88. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem. 2001;276:8403-8408.
89. Hirschhorn JN, Altshuler D. Once and again-issues surrounding replication in genetic association studies. J Clin Endocrinol Metab. 2002;87:4438-4441.
90. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4:45-61.
91. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141:137-147.
92. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.